OP
ALNY icon

ORG Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

ORG Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$29K Sell
73
-7
-9% -$3.1K 0.01% 705
2025
Q3 		$36.5K Buy
80
+33
+70% +$13.4K 0.01% 654
2025
Q2 		$15.1K Buy
47
+11
+31% +$3.04K ﹤0.01% 820
2025
Q1 		$9.2K Buy
+36
New +$9.25K ﹤0.01% 814

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ORG Partners's ALNY Position: Q4 2025 in Review

ORG Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 8.8% in Q4 2025, selling an estimated $3.1K and leaving 73 shares worth $29K. The position accounts for 0.01% of the portfolio, ranked #705.

ORG Partners first reported a position in ALNY in Q1 2025 and has held it in 4 quarters since. The position peaked at $36.5K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • ORG Partners held 73 shares of Alnylam Pharmaceuticals worth $29K as of Q4 2025.
  • ORG Partners sold 7 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $3.1K.
  • Alnylam Pharmaceuticals made up 0.01% of ORG Partners's portfolio in Q4 2025, its #705 holding.
  • ORG Partners first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • ORG Partners's Alnylam Pharmaceuticals position peaked at $36.5K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.